AIDX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

AIDX ▲ +9.15% at T+20d

NEUTRAL call ✓ call won +9.15% · α vs SPY +0.25% · entry $1.64 → $1.79

Next anchor: T+60d in 5d

Currently $0.9600 · -41.46% from $1.64 entry

Entry anchored
Mar 23, 02:40 PM ET
via Databento tick

T+1d

-1.22%

call -1.22% · α -1.79%

$1.62

settled 3mo ago

T+5d

+14.63%

call +14.63% · α +15.06%

$1.88

settled 2mo ago

T+20d

+9.15%

call +9.15% · α +0.25%

$1.79

settled 7w ago

T+60d

—

call — · α —

—

in 5d

Price Chart

Loading chart...

Executive Summary

20/20 Biolabs (AIDX) announced an exclusive U.S. technology license and access agreement with ROKIT Healthcare to integrate ROKIT’s chronic kidney disease (CKD) prediction algorithm into 20/20’s Longevity Platform. ROKIT will reimburse one-third of agreed sales and marketing expenses in exchange for a running royalty on net sales, with potential for expanded commercialization in Korea and other East Asian markets.

Actionable Insight

Monitor for future disclosures on royalty income, commercial performance of the enhanced OneTest for Longevity, and any announcement of the East Asian commercialization agreement. The partnership may improve platform differentiation in the longevity analytics market, but near-term financial impact is uncertain.

Key Facts

20/20 Biolabs entered into an exclusive U.S. technology license agreement with ROKIT Healthcare.
ROKIT’s CKD prediction algorithm will be integrated into 20/20’s OneTest for Longevity platform.
ROKIT will reimburse 20/20 for one-third of mutually agreed sales and marketing expenses.
ROKIT will receive a running royalty on net sales of the combined product.
Potential future agreement for ROKIT to commercialize 20/20’s platform in Korea and other East Asian markets is under discussion.
No financial terms such as deal value, revenue projections, or royalty rates were disclosed.

Financial Impact

Unknown — no specific financial figures disclosed; potential future revenue from royalties and shared marketing funding.

revenueoperating expensesroyalty income

Risk Factors

No guaranteed revenue — financial benefit depends on future product adoption and sales.
Dependence on ROKIT’s commercial execution, particularly in international markets.
Forward-looking statements dominate the release; actual outcomes may differ materially.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3261237

7 reports for AIDX

T+1T+5T+20T+60

100% Hit rate 4 of 4 directional calls best @ T+20▲ +37.42%Apr 28, 2026

Filters

Reports for AIDX — sortable, filterable
	Type				Now
May 26, 2026 17d ago	8-K NEUTRAL ★ 2/10	$0.9700 $0.8400	▼ −13.40%	▼ −13.87%	$0.9600 (−1.03%)
May 20, 2026 23d ago	8-K BEARISH ★ 6/10	$1.21 $0.9500	▲ +21.49%	▲ +23.09%	$0.9600 (+20.66%)
May 20, 2026 23d ago	Press Release BEARISH ★ 6/10	$1.21 $0.9500	▲ +21.49%	▲ +23.09%	$0.9600 (+20.66%)
Apr 28, 2026 6w ago	8-K BEARISH ★ 6/10	$1.55 $1.49	▲ +3.87%	▲ +5.56%	$0.9600 (+38.06%)
Apr 13, 2026 8w ago	EFFECT NEUTRAL ★ 6/10	$1.85 $1.71	▼ −7.57%	▼ −10.86%	$0.9600 (−48.11%)
Mar 27, 2026 11w ago	Press Release BULLISH ★ 7/10	$1.80 $2.02	▲ +12.22%	▲ +8.36%	$0.9600 (−46.67%)
Mar 24, 2026 11w ago	Press Release MIXED ★ 5/10	$1.64 $1.88	▲ +14.63%	▲ +15.06%	$0.9600 (−41.46%)

US Market Status

Market Closed — Opens Mon (48h 51m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access